ThoroughFare atrial pressure controller device to create a controlled interatrial right-to-left shunt in advanced pulmonary arterial hypertension – A pilot study Authors: Bojja Venkata Satya Roopesh, Girija Haritha, S. V. Kishore, Muthukumaran Chinnasamy Sivaprakasam, Shreesha Maiya, Saileela Rajan, Pramod Sagar, Kothandam Sivakumar Published: 2024 ABSTRACT ABSTRACTBackground:Atrial flow regulators are used in patients with pulmonary arterial hypertension (PAH) who present with syncope or advanced heart failure. The ThoroughFare atrial pressure controller (Meril Life Sciences, Vapi, India) is a new device for similar use. The differences in structural design include a cable–screw release mechanism and a low profile.Methods:A multi-institutional study assessed the feasibility and safety of this device and reported short-term follow-up. This device, with an 8-mm fenestration diameter, was deployed after transseptal puncture using a 12F sheath.Results:Between April 2023 and June 2024, 15 symptomatic patients aged 5–39 years, including four children, received this implant after dual pulmonary vasodilator pharmacotherapy for at least 2 years. Etiology included idiopathic PAH in eight patients, hereditary PAH in two, operated shunt lesions in four, and human immunodeficiency virus-associated PAH in one patient. The key indication was recurrent syncope in 11 and right heart failure in the rest. The mean N-terminal pro-brain natriuretic peptide was 2414 ± 2046 pg/mL. The hemodynamic assessment revealed high right atrial pressures in 80% of patients, low cardiac index in half, and suprasystemic pulmonary pressures in four patients. The procedure was completed in all patients without any complications. Pulse oximeter saturations dropped from 98% ±2% to 92% ±4%. Symptoms improved over a median follow-up of 8 months, and the device patency was confirmed in all patients except one patient who died 5 months postprocedure after a heart–lung transplantation.Conclusion:ThoroughFare atrial pressure controller implantation was feasible and safe for all patients with severe PAH without any complications. Longer follow-up with more patients is needed to ascertain the functional improvements. INTRODUCTION Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in right ventricular (RV) afterload, leading to its dysfunction, systemic venous congestion, and a fall in cardiac output.[1] The presence of an interatrial right-to-left shunt improves left ventricular filling, preserves cardiac output, and increases survival at the expense of arterial hypoxemia.[2] Atrial septostomy prevents syncope due to pulmonary hypertensive crisis. Reduction in RV volume shifts Starling’s curve to the left from its declining limb and improves its ejection fraction.[3] Septostomy is a bridge to lung transplantation or a destination in nontransplantable patients.[4] Balloon and blade septostomy fail to maintain a predictable patency.[56] With custom-fenestrated Amplatzer septal occluders, the fenestrations may close on follow-up.[78] Atrial septal stents create controllable and predictable shunts but may embolize and offer technical challenges.[91011] The atrial flow regulator (AFR) (Occlutech Inc, Helsingborg, Sweden) is an implantable double-disc nitinol device with a predefined diameter that has been shown to improve hemodynamic parameters and survival in sick patients with PAH.[1213] Even though the device received a “breaking device designation” for left atrial decompression in heart failure, it did not receive approval from the United States Food and Drugs Administration for clinical use in PAH. As this device is not widely available worldwide, there is an impending need for alternative options. The ThoroughFare atrial pressure controller device (Meril Life Sciences, Vapi, India) is a similar double-disc nitinol wire mesh device with central fenestration but with distinct differences in design. This device was used on a compassionate basis with special access after institutional ethical committee approval, as the alternative AFR device was not available for clinical use in India. We present a multicenter first-in-man use of this device in patients with PAH. We aim to study the feasibility of implantation, device safety, and performance by assessing its patency. METHODS A nonrandomized multi-institutional pilot project assessed the utility of the ThoroughFare device in patients with advanced PAH and syncope or right heart failure. A detailed informed written consent was obtained after explaining the principle of atrial septostomy, procedural details, device utility, nature of the implant, possible outcomes, and need for continued follow-up investigations, including transesophageal echocardiography, agitated saline contrast echocardiography, and cardiac catheterization. Institutional ethical committee approval was obtained for the compassionate use of this implant in patients with PAH as an alternative to balloon atrial septostomy or Occlutech AFR device. Aims of the study The primary aim of the study was to determine the feasibility of implanting the ThoroughFare device in patients with PAH and analyze the technical challenges during the procedure or the need for modifications during the implantation. The secondary aim was to study safety by assessing the incidence of immediate postprocedural device-related severe adverse events, improvement of patient symptoms, and the mechanical performance shown by its short-term patency. Patient selection Patients aged above 5 years diagnosed with severe PAH who clinically presented either with syncope/presyncope or right heart failure presenting with systemic venous congestion were considered for ThoroughFare implantation after informed consent. Key inclusion criteria were Type I PAH with mean pulmonary pressure of >20 mmHg and pulmonary capillary wedge pressure of <15 mmHg.[14] Type II, III, and IV PAH were excluded. As the device implantation warranted a 12F introducer sheath, patients younger than 5 years and weighing <15 kg were excluded. Patients with known nickel allergy, inferior vena caval or iliac vein thrombosis, active sepsis, coagulopathy, and pregnancy were excluded. Device specifications ThoroughFare atrial pressure controller is a self-expandable double-disc nitinol mesh device with a wire thickness of 100 μ connected by a waist that has a central fenestration [Figure 1]. A connecter jacket is located on the proximal right atrial disc of the device, which facilitates to connect to a male screw end of a delivery cable. It is designed with a fenestration diameter of 8 mm and is smaller in profile than the Occlutech AFR. The cable–screw connection, located on the proximal right atrial disc, is similar to most nitinol occluder devices and simplifies its deployment, unlike the pistol-pusher release and lock mechanism of the AFR. The waist width is 5 mm, and the outer diameter of the discs is 21 mm on either side. The central fenestration is 8 mm in diameter. ThoroughFare atrial pressure controller device is a double-disc nitinol device with a central fenestration. The left atrial side of the device (a) is distinguished from the right atrial side of the device (b) by the presence of the female end of the screw on the latter side. Profile view (c) demonstrating the waist with the fenestration Procedural details After preprocedural intravenous administration of a single dose of antibiotic, the right femoral vein and artery were accessed. The cardiac index was calculated using Fick oximetry by sampling the pulmonary artery and aorta. A complete hemodynamic pressure recording was followed by acute vasodilator testing using inhaled nitric oxide (40 parts per million) administered for 10 min and oxygen through a nonrebreathing tight-fitting mask whenever nitric oxide was available. No other agents were used for acute vasodilator testing. An interatrial septal puncture was done using a Brockenbrough needle in the region of the oval fossa on fluoroscopic guidance after positioning a pigtail catheter in the noncoronary sinus of the aortic root. A 12F-long Mullins sheath (Cook Medical, Bloomington, IN) was placed in the left atrium across the oval fossa puncture site. As part of a pilot project, all patients received the same size device with a fenestration diameter of 8 mm, disc diameter of 21 mm, and interdisc width of 5 mm. Whenever the atrial septum was found to be thick during puncture or in patients with previous pericardial patch closure of an atrial septal defect, the puncture site was predilated with a high-pressure 8-mm Mustang balloon (Boston Scientific Corporation, Natick, MA) before placing the delivery system. Unfractionated heparin was administered after the septal puncture at 100 units/kg dose to a target-activated clotting time of >250 s. The atrial pressure controller device was screwed to the delivery cable and introduced into the Mullins sheath through a loader after flushing with saline. Under fluoroscopic and echocardiography guidance, the left atrial disc and part of the connecting waist were initially deployed in the left atrium. After pulling the device and tugging it against the atrial septum, the right atrial device was deployed [Figure 2]. The device was released after a pull–push wiggle under echocardiographic and fluoroscopic guidance. The patency of the device was confirmed, demonstrating a right-to-left shunt on bubble contrast echocardiography performed through the side arm of the delivery sheath [Figure 3]. Dual antiplatelet therapy with aspirin and clopidogrel was administered immediately following the procedure. Considering the strong likelihood of right-to-left shunt with potential for systemic thromboembolism, antiplatelets were continued indefinitely if tolerated. The device is introduced through a long sheath that is advanced through the atrial septum into the left atrium after septal puncture. After deploying the left atrial disc, the device is pulled against the atrial septum to deploy the right atrial disc on the other side ThoroughFare device is deployed across the atrial septum after septal puncture (a) in a patient with a previous surgical pericardial patch closure of the atrial septal defect, and the device is released (b). The apical four-chamber echocardiographic view (c) showing a dilated right atrium and right ventricle, which are filled with agitated saline contrast. Contrast spills into the left atrium and left ventricle through the device. A three-dimensional left atrial enface view from transesophageal echocardiography (d) demonstrating the fenestration. RV: Right ventricle, RA: Right atrium, LA: Left atrium, LV: Left ventricle Follow-up details Patients were followed up for relief of syncope, improvement of features of right heart failure, procedural adverse effects such as vascular complications, and device-related adverse effects such as thromboembolic phenomenon, infection, arrhythmias, and chest pain. The echocardiogram on follow-up focused on the patency of the device. As this was a pilot project to assess the feasibility of implantation, changes in echocardiographic parameters and biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) were beyond the scope of this study. Data collection and analysis Baseline patient data included demographics, pulse oximetry, symptoms, etiology of PAH, and NT-proBNP levels. RV systolic dysfunction was defined on echocardiography using either one or many of the following parameters, such as RV free-wall strain through speckle tracking >20%, tricuspid annular plane systolic excursion (TAPSE) <16 mm, fractional area change <35%, or RV tissue Doppler-derived S’ velocity <10 cm/s. Hemodynamic parameters included cardiac index and pulmonary vascular resistance. Procedural details included fluoroscopic duration, radiation dose, complications (if any), and device patency on contrast echocardiography. Categorical variables were expressed as proportions, and continuous variables as median with range. Analysis of this descriptive study was done using SPSS statistical software, version 29(IBM, Armonk, NY). RESULTS The study analyzed 15 procedures from four South Indian tertiary cardiac care institutions between April 2023 and June 2024. The demographic and hemodynamic parameters are detailed in Table 1. All patients received at least 2 years of dual pulmonary vasodilator therapy before the intervention. Three patients received selexipag in addition. Four patients showed clinically manifest edema despite the use of diuretics. Among the four patients who had residual PAH after repair of congenital heart diseases, two were operated for atrial septal defect, one was operated for ventricular septal defect, and one underwent device closure of atrial septal defect. Syncope was the most common reason for the intervention. Echocardiogram showed pericardial effusion in 6 patients, noncollapsing congested inferior vena cava in 10 patients, moderate tricuspid regurgitation in 8, and severe regurgitation in 4 patients, and one or more findings of RV systolic dysfunction in all patients. Table 1Patient clinical detailsEtiologyAgeWeightWHO classPre-SpO2NT ProBNPDrugsRAPAPAortaPVRIRatioPost-Spo2ASD surgery5369397933Endothelin receptor antagonist, phosphodiesterase-5 inhibitor12110/40/70120/70/85230.8585VSD surgery2968297895Endothelin receptor antagonist, phosphodiesterase-5 inhibitor1480/35/5590/65/72250.6894Idiopathic PAH8322974250Endothelin receptor antagonist, phosphodiesterase-5 inhibitor, selexipag460/30/40105/70/886.10.3896Idiopathic PAH37672961050Endothelin receptor antagonist, phosphodiesterase-5 inhibitor10105/50/7095/60/7528.40.9591Hereditary PAH30483971630Endothelin receptor antagonist, phosphodiesterase-5 inhibitor, selexipag1790/32/5695/66/7829.40.8190HIV related PAH4550399576Endothelin receptor antagonist, phosphodiesterase-5 inhibitor1090/38/57115/70/92174.3693Idiopathic PAH3059.73991078Endothelin receptor antagonist, phosphodiesterase-5 inhibitor13137/51/81112/68/8429.6185ASD device70503965248Endothelin receptor antagonist, phosphodiesterase-5 inhibitor1374/32/53122/66/8817.50.8189SVD surgery1538.93991123Endothelin receptor antagonist, phosphodiesterase-5 inhibitor9103/46/6785/43/5932.91.0692Hereditary PAH514.83981120Endothelin receptor antagonist, phosphodiesterase-5 inhibitor680/27/48106/70/8911.50.4898Idiopathic PAH734.33962390Endothelin receptor antagonist, phosphodiesterase-5 inhibitor10112/67/90120/75/9128.51.0196Idiopathic PAH1248.53921980Endothelin receptor antagonist, phosphodiesterase-5 inhibitor, selexipag1480/42/5796/64/7812.60.6595Idiopathic PAH2776394787Endothelin receptor antagonist, phosphodiesterase-5 inhibitor16116/44/60108/72/8927.20.9394Idiopathic PAH3868.24947159Endothelin receptor antagonist, phosphodiesterase-5 inhibitor1494/34/54122/63/8089Idiopathic PAH8273984510Endothelin receptor antagonist, phosphodiesterase-5 inhibitor880/26/50125/65/93180.4998Ratio-pulmonary vascular resistance/systemic vascular resistance ratio. Units-age (years), weight (kg), pressures (mm) of mercury, vascular resistance in wood units. WHO: World Health Organization functional class, NT-proBNP: N-terminal pro-brain natriuretic peptide (pg/mL), RA: Mean right atrial pressure, PAP: Pulmonary artery systolic/diastolic/mean pressure, Aorta: Aortic systolic/diastolic/mean pressure, PVRI: Pulmonary vascular resistance index, ASD: Atrial septal defect, VSD: Ventricular septal defect, SVD: Sinus venosus defect, PAH: Pulmonary arterial hypertension, Pre-SpO2: preprocedural pulse oximeter saturation, Post-SpO2: Postprocedural pulse oximeter saturation, HIV: Human immunodeficiency virus Patient clinical details Ratio-pulmonary vascular resistance/systemic vascular resistance ratio. Units-age (years), weight (kg), pressures (mm) of mercury, vascular resistance in wood units. WHO: World Health Organization functional class, NT-proBNP: N-terminal pro-brain natriuretic peptide (pg/mL), RA: Mean right atrial pressure, PAP: Pulmonary artery systolic/diastolic/mean pressure, Aorta: Aortic systolic/diastolic/mean pressure, PVRI: Pulmonary vascular resistance index, ASD: Atrial septal defect, VSD: Ventricular septal defect, SVD: Sinus venosus defect, PAH: Pulmonary arterial hypertension, Pre-SpO2: preprocedural pulse oximeter saturation, Post-SpO2: Postprocedural pulse oximeter saturation, HIV: Human immunodeficiency virus Among the hemodynamic parameters, 80% of patients showed elevated right atrial pressures despite using diuretics when clinically indicated. All patients had severe PAH, and four among them showed suprasystemic pulmonary artery pressures. Half of the patients had low cardiac output. The resistance ratio was > 0.6 in all patients. Only two of the 11 patients who underwent acute vasodilator testing with inhaled nitric oxide showed some response. Even though pulmonary artery mean pressure was reduced by 10 mmHg in these two patients, the absolute value did not decrease below 40 mmHg to satisfy Sitbon criteria.[15] However, symptoms of recurrent syncope in these two patients warranted the intervention. The procedure was performed under general anesthesia and transesophageal echocardiographic guidance in 10 of the 15 interventions. Others had local anesthesia and transthoracic echocardiographic guidance only. There were no procedural difficulties during transseptal puncture or device implantation. The median fluoroscopic duration was 15 min and ranged from 4 to 56 min. The median dose area product was 24,989 mGray/cm2, ranging from 16,283 to 72,796 mGray/cm2. There were no procedural complications. The median follow-up duration was 8.5 months. The procedure was done as the destination therapy in all except one patient who was listed for heart–lung transplantation. This patient, aged 30 years, had suprasystemic pulmonary artery pressures and did not show a response to inhaled nitric oxide. She underwent transplantation 5 months after the implantation but succumbed in the posttransplant period. One patient living abroad was lost to follow-up. All other patients survived till the last follow-up. All patients reported freedom from syncope and marginal improvement of functional class. The patency of the device on echocardiogram was proven in all patients. DISCUSSION Annual mortality of patients with severe PAH averages 11.8% despite recent advances in medical therapy targeting different pathogenic pathways.[16] Advances in transplant surgery have failed to change the outcome in patients with PAH substantially.[1] Mortality following transplant is higher in PAH compared to other lung diseases.[17] Transplantation remains an option for only a third of patients in developed countries and is largely unavailable in developing economies. While earlier reports of balloon atrial septostomy showed the utility of the procedure in improving symptoms, severe hypoxemia caused a mortality of 7.2% within 24 h following the procedure.[18] The first reports of controlled septostomy created using Occlutech AFR devices that offered fenestration diameters of 4 mm, 6 mm, 8 mm, and 10 mm proved improved survival of patients following the intervention.[1213] This device provided a prespecified fenestration diameter that avoided undue disproportionate hypoxia that might result after balloon or blade septostomy.[1213] This device is still not universally available and has yet to receive approval for routine clinical use by the United States Food and Drug Administration. Even though compassionate use of this device was initially permitted in India on an import license, it was withdrawn later. ThoroughFare atrial flow controller device made in India was designed as an alternative to the Occlutech AFR device that was withdrawn from India. The device had two significant differences in the structural design. The pilot project used a device with a fixed fenestration diameter of 8 mm. The device was released by a screw–cable mechanism familiar to all interventional cardiologists who performed device closure of atrial and ventricular septal defects and arterial ducts using a similar screw–cable release. The device could be preloaded during implantation in a 10F–11F short introducer sheath, indicating a smaller profile than the AFR device. However, this first-in-man pilot project used a 12F Mullins sheath for deployment in all patients. As a large septostomy carried a risk of severe intolerable hypoxemia, left ventricular failure, and mortality, we used 8-mm fenestration in all patients in this pilot study.[5] In comparison to the release mechanism of the ThoroughFare device, AFR devices had a complex lock mechanism of the pistol pusher release.[12] The pilot study showed the feasibility of implantation in all patients where this intervention was performed. As the procedure was performed in four institutions that routinely performed catheter interventions through experienced operators, there were no procedural complications, including any complications of transseptal puncture. Transesophageal echocardiography in ten patients facilitated transseptal puncture. However, transesophageal echocardiographic guidance was not mandatory, which would often warrant intubation and general anesthesia. The device retained patency till the last follow-up in all surviving patients. The only mortality was in a sick patient where the atrial flow controller acted as a bridge to transplantation. Following the transplantation performed 5 months after the catheter intervention, the patient succumbed during the postoperative period. The studies done in a single center using AFRs clearly indicated immediate hemodynamic improvement of cardiac index and systemic oxygen transport, an increase of 6-min walk distance, relief of syncope, and a longer follow-up of up to 53 months.[1213] The ThoroughFare device was similar to the AFR in the basic design. This retrospective study showed the feasibility of implantation, thereby providing an alternative to the regulator device. Being a multicenter retrospective pilot study to demonstrate the technical feasibility, a longer follow-up is required to prove sustained improvement of patient outcomes. The short-term gains of the controlled right-to-left shunt were improved left ventricular filling and increased cardiac output.[13] Late benefits included polycythemia induced by hypoxemia, which improved oxygen delivery, and RV decompression, which improved contractility.[19] REVEAL 2.0 risk scores prognosticate patients with severe PAH and predict their 1-year mortality based on clinical, laboratory, hemodynamic, and echocardiographic parameters.[20] This score increased in heritable PAH noted in two patients in our group, the World Health Organization Class III and IV identified in 12 patients, high natriuretic peptide levels identified in half of our patients, and pericardial effusion noted in six of our cohort. The procedure was completed in all patients without any complications. The patency of the device persisted till the last follow-up in all survivors. Limitations As this is a pilot project to describe a novel device for palliating patients with severe PAH, the number of patients enrolled in this study is small. Being a retrospective data collection from the four centers that participated in the study, some parameters, such as 6-min walk distance and RV echocardiographic parameters, could not be obtained in all the case records. The device has been used only for the last year, so the follow-up duration is also short. The procedural outcome was not compared to other modes of septostomy, such as balloon septostomy or atrial stent implantation. Cardiopulmonary exercise testing and analysis of oxygen consumption could have proven the real improvement of functional parameters, but the institutions lacked facilities for such testing. As the follow-up duration was short and <1 year in the majority, improvement of 6-min walk distance or NT-proBNP levels would be shown only after a few months. CONCLUSIONS This pilot project of the ThoroughFare atrial flow controller device showed the feasibility of implantation in all patients with PAH above 5 years of age without any procedural complications. The device showed patency on short-term follow-up while patients received dual antiplatelet drugs. Continued follow-up with a larger number of patients would be required to prove the long-term patency of this device and observe the improvement in functional outcomes. Conflicts of interest There are no conflicts of interest.